We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 106.29 | 4 | 09:07:33 |
From May 2023 to May 2024
By Ben Glickman
Abbott Laboratories' diagnostic for patients with a rare form of blood cancer was approved by the U.S. Food and Drug Administration.
The FDA approved the RealTime IDH1 Assay as a companion diagnostic for the selection of relapsed or refractory myelodysplastic syndromes with a mutation in isocitrate dehydrogenase-1.
The FDA said MDS, a form of blood cancer, can be caused by mutations in bone marrow cells.
The FDA also approved Tibsovo for the treatment of adult patients with the same form of MDS, the first targeted therapy approved for the indication.
Tibsovo was previously approved for some adults with acute myeloid leukemia and cholangiocarcinoma.
Abbott's test was previously approved as a companion diagnostic to identify AML patients with the same genetic mutation for treatment with Tibsovo or Rezlidhia.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 24, 2023 16:58 ET (20:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
